Inflammatix Names Martín Vazquez as Chief Operating Officer to Drive National Scale-Up of TriVerity™ Test System
Seasoned medtech executive joins as hospital adoption accelerates for breakthrough diagnostic in acute infection and sepsis care
SUNNYVALE, Calif., June 10, 2025 /PRNewswire/ — Inflammatix, a leader in AI-powered immune response diagnostics, today announced the appointment of Martín Vazquez as chief operating officer (COO). The hire marks a major milestone in the company’s commercial expansion as its flagship TriVerity™ Test System gains traction among U.S. hospitals.
Mr. Vazquez’s arrival comes as TriVerity—FDA-cleared in January 2025—enters clinical use to help emergency physicians rapidly identify infection and determine illness severity in patients with suspected sepsis. His operational leadership will be central to expanding production and delivery to meet rising demand.
